1
|
González-Montero J, Rojas CI, Burotto M. MAP4K4 and cancer: ready for the main stage? Front Oncol 2023; 13:1162835. [PMID: 37223681 PMCID: PMC10200945 DOI: 10.3389/fonc.2023.1162835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 04/06/2023] [Indexed: 05/25/2023] Open
Abstract
MAP4K4 is a serine/threonine kinase that belongs to the MAP kinase family and plays a critical role in embryogenesis and cellular migration. It contains approximately 1,200 amino acids and has a molecular mass of 140 kDa. MAP4K4 is expressed in most tissues where it has been examined and its knockout is embryonic lethal due to impaired somite development. Alterations in MAP4K4 function have a central role in the development of many metabolic diseases such as atherosclerosis and type 2 diabetes, but have recently been implicated in the initiation and progression of cancer. For example, it has been shown that MAP4K4 can stimulate the proliferation and invasion of tumor cells by activating pro-proliferative pathways (such as the c-Jun N-terminal kinase [JNK] and mixed-lineage protein kinase 3 [MLK3] pathways), attenuate anti-tumor cytotoxic immune responses, and stimulate cell invasion and migration by altering cytoskeleton and actin function. Recent in vitro experiments using RNA interference-based knockdown (miR) techniques have shown that inhibition of MAP4K4 function reduces tumor proliferation, migration, and invasion, and may represent a promising therapeutic approach in many types of cancer such as pancreatic cancer, glioblastoma, and medulloblastoma, among others. Over the last few years, specific MAP4K4 inhibitors such as GNE-495 have been developed but have not yet been tested in cancer patients. However, these novel agents may be useful for cancer treatment in the future.
Collapse
|
2
|
Kumar V, Gupta S, Chaurasia A, Sachan M. Evaluation of Diagnostic Potential of Epigenetically Deregulated MiRNAs in Epithelial Ovarian Cancer. Front Oncol 2021; 11:681872. [PMID: 34692473 PMCID: PMC8529058 DOI: 10.3389/fonc.2021.681872] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 09/08/2021] [Indexed: 12/12/2022] Open
Abstract
Background Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies among women worldwide. Early diagnosis of EOC could help in ovarian cancer management. MicroRNAs, a class of small non-coding RNA molecules, are known to be involved in post-transcriptional regulation of ~60% of human genes. Aberrantly expressed miRNAs associated with disease progression are confined in lipid or lipoprotein and secreted as extracellular miRNA in body fluid such as plasma, serum, and urine. MiRNAs are stably present in the circulation and recently have gained an importance to serve as a minimally invasive biomarker for early detection of epithelial ovarian cancer. Methods Genome-wide methylation pattern of six EOC and two normal ovarian tissue samples revealed differential methylation regions of miRNA gene promoter through MeDIP-NGS sequencing. Based on log2FC and p-value, three hypomethylated miRNAs (miR-205, miR-200c, and miR-141) known to have a potential role in ovarian cancer progression were selected for expression analysis through qRT-PCR. The expression of selected miRNAs was analyzed in 115 tissue (85 EOC, 30 normal) and 65 matched serum (51 EOC and 14 normal) samples. Results All three miRNAs (miR-205, miR-200c, and miR-141) showed significantly higher expression in both tissue and serum cohorts when compared with normal controls (p < 0.0001). The receiver operating characteristic curve analysis of miR-205, miR-200c, and miR-141 has area under the curve (AUC) values of 87.6 (p < 0.0001), 78.2 (p < 0.0001), and 86.0 (p < 0.0001), respectively; in advance-stage serum samples, however, ROC has AUC values of 88.1 (p < 0.0001), 78.9 (p < 0.0001), and 86.7 (p < 0.0001), respectively, in early-stage serum samples. The combined diagnostic potential of the three miRNAs in advance-stage serum samples and early-stage serum samples has AUC values of 95.9 (95% CI: 0.925-1.012; sensitivity = 96.6% and specificity = 80.0%) and 98.1 (95% CI: 0.941-1.021; sensitivity = 90.5% and specificity = 100%), respectively. Conclusion Our data correlate the epigenetic deregulation of the miRNA genes with their expression. In addition, the miRNA panel (miR-205 + miR-200c + miR-141) has a much higher AUC, sensitivity, and specificity to predict EOC at an early stage in both tissue and serum samples.
Collapse
Affiliation(s)
- Vivek Kumar
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| | - Sameer Gupta
- Department of Surgical Oncology, King George Medical University, Lucknow, India
| | - Amrita Chaurasia
- Department of Gynaecology and Obstetrics, Motilal Nehru Medical College, Allahabad, India
| | - Manisha Sachan
- Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, India
| |
Collapse
|
3
|
Li Q, Li B, Lu CL, Wang JY, Gao M, Gao W. LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma. Cancer Gene Ther 2021; 28:1046-1057. [PMID: 33311569 DOI: 10.1038/s41417-020-00267-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 11/18/2020] [Indexed: 01/30/2023]
Abstract
LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEX), LINC01857 expression was found upregulated in both DLBCL tissues and cells. Cell proliferation and flow cytometry assays showed that LINC01857 promoted proliferation and cell cycle, but suppressed apoptosis in DLBCL cells. Bioinformatics analysis and luciferase reporter assay confirmed that LINC01857 may serve as a sponge for miR-141-3p and miR-141-3p may target MAP4K4. Mechanically, the regulatory action of miR-141-3p/MAP4K4 on DLBCL cellular behaviors was regulated by LINC01857. In addition, LINC01857 could increase the activity of PI3K/mTOR pathway and facilitate the EMT process in a miR-141-3p-mediated manner in DLBCL. Our data illustrated that the LINC01857/miR-141-3p/MAP4K4 might function as a promising therapeutic avenue for DLBCL treatment.
Collapse
Affiliation(s)
- Qian Li
- School of Medical Laboratory, Weifang Medical University, Weifang, Shandong, 261053, PR China
| | - Bao Li
- Department of Urology, Weifang People's Hospital, Weifang, Shandong, 261000, PR China
| | - Chang-Liang Lu
- School of Clinical Medicine, Weifang Medical University, Weifang, Shandong, 261053, PR China
| | - Jing-Ye Wang
- Department of Pathology, Weifang Maternal and Child Health Care Hospital, Weifang, Shandong, 261011, PR China
| | - Min Gao
- Department of Otolaryngology, Weifang People's Hospital, Weifang, Shandong, 261000, PR China
| | - Wei Gao
- Key Lab for Immunology in Universities of Shandong Province, Weifang Medical University, Weifang, Shandong, 261053, PR China.
| |
Collapse
|
4
|
Ragusa M, Santagati M, Mirabella F, Lauretta G, Cirnigliaro M, Brex D, Barbagallo C, Domini CN, Gulisano M, Barone R, Trovato L, Oliveri S, Mongelli G, Spitale A, Barbagallo D, Di Pietro C, Stefani S, Rizzo R, Purrello M. Potential Associations Among Alteration of Salivary miRNAs, Saliva Microbiome Structure, and Cognitive Impairments in Autistic Children. Int J Mol Sci 2020; 21:ijms21176203. [PMID: 32867322 PMCID: PMC7504581 DOI: 10.3390/ijms21176203] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 08/16/2020] [Accepted: 08/25/2020] [Indexed: 12/26/2022] Open
Abstract
Recent evidence has demonstrated that salivary molecules, as well as bacterial populations, can be perturbed by several pathological conditions, including neuro-psychiatric diseases. This relationship between brain functionality and saliva composition could be exploited to unveil new pathological mechanisms of elusive diseases, such as Autistic Spectrum Disorder (ASD). We performed a combined approach of miRNA expression profiling by NanoString technology, followed by validation experiments in qPCR, and 16S rRNA microbiome analysis on saliva from 53 ASD and 27 neurologically unaffected control (NUC) children. MiR-29a-3p and miR-141-3p were upregulated, while miR-16-5p, let-7b-5p, and miR-451a were downregulated in ASD compared to NUCs. Microbiome analysis on the same subjects revealed that Rothia, Filifactor, Actinobacillus, Weeksellaceae, Ralstonia, Pasteurellaceae, and Aggregatibacter increased their abundance in ASD patients, while Tannerella, Moryella and TM7-3 decreased. Variations of both miRNAs and microbes were statistically associated to different neuropsychological scores related to anomalies in social interaction and communication. Among miRNA/bacteria associations, the most relevant was the negative correlation between salivary miR-141-3p expression and Tannerella abundance. MiRNA and microbiome dysregulations found in the saliva of ASD children are potentially associated with cognitive impairments of the subjects. Furthermore, a potential cross-talking between circulating miRNAs and resident bacteria could occur in saliva of ASD.
Collapse
Affiliation(s)
- Marco Ragusa
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
- Oasi Research Institute—IRCCS, 94018 Troina, Italy
| | - Maria Santagati
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
| | - Federica Mirabella
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Giovanni Lauretta
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Matilde Cirnigliaro
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Duilia Brex
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Cristina Barbagallo
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Carla Noemi Domini
- Department of Clinical and Experimental Medicine, Section of Child and Adolescent Psychiatry, University of Catania, 95123 Catania, Italy; (C.N.D.); (M.G.); (R.B.); (R.R.)
| | - Mariangela Gulisano
- Department of Clinical and Experimental Medicine, Section of Child and Adolescent Psychiatry, University of Catania, 95123 Catania, Italy; (C.N.D.); (M.G.); (R.B.); (R.R.)
| | - Rita Barone
- Department of Clinical and Experimental Medicine, Section of Child and Adolescent Psychiatry, University of Catania, 95123 Catania, Italy; (C.N.D.); (M.G.); (R.B.); (R.R.)
| | - Laura Trovato
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
| | - Salvatore Oliveri
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
| | - Gino Mongelli
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
- Bio-nanotech Research and Innovation Tower (BRIT), University of Catania, 95123 Catania, Italy
| | - Ambra Spitale
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
| | - Davide Barbagallo
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Cinzia Di Pietro
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
| | - Stefania Stefani
- Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy; (M.S.); (L.T.); (S.O.); (G.M.); (A.S.); (S.S.)
| | - Renata Rizzo
- Department of Clinical and Experimental Medicine, Section of Child and Adolescent Psychiatry, University of Catania, 95123 Catania, Italy; (C.N.D.); (M.G.); (R.B.); (R.R.)
| | - Michele Purrello
- Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G. Sichel, University of Catania, 95123 Catania, Italy; (M.R.); (F.M.); (G.L.); (M.C.); (D.B.); (C.B.); (D.B.); (C.D.P.)
- Correspondence:
| |
Collapse
|
5
|
Giuliani A, Zuccarini M, Cichelli A, Khan H, Reale M. Critical Review on the Presence of Phthalates in Food and Evidence of Their Biological Impact. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2020; 17:E5655. [PMID: 32764471 PMCID: PMC7460375 DOI: 10.3390/ijerph17165655] [Citation(s) in RCA: 143] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 08/01/2020] [Accepted: 08/03/2020] [Indexed: 12/14/2022]
Abstract
Phthalates are a huge class of chemicals with a wide spectrum of industrial uses, from the manufacture of plastics to food contact applications, children's toys, and medical devices. People and animals can be exposed through different routes (i.e., ingestion, inhalation, dermal, or iatrogenic exposure), as these compounds can be easily released from plastics to water, food, soil, air, making them ubiquitous environmental contaminants. In the last decades, phthalates and their metabolites have proven to be of concern, particularly in products for pregnant women or children. Moreover, many authors reported high concentrations of phthalates in soft drinks, mineral waters, wine, oil, ready-to-eat meals, and other products, as a possible consequence of their accumulation along the food production chain and their accidental release from packaging materials. However, due to their different physical and chemical properties, phthalates do not have the same human and environmental impacts and their association to several human diseases is still under debate. In this review we provide an overview of phthalate toxicity, pointing out the health and legal issues related to their occurrence in several types of food and beverage.
Collapse
Affiliation(s)
- Angela Giuliani
- "G.d'Annunzio" School of Advanced Studies, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy
| | - Mariachiara Zuccarini
- Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy
- Aging Research Center, Ce.S.I., "G. d'Annunzio" University Foundation, 66100 Chieti, Italy
| | - Angelo Cichelli
- Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy
| | - Haroon Khan
- Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan
| | - Marcella Reale
- Department of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy
- Interuniversity Center on Interactions between Electromagnetic Fields and Biosystems, National Research Council-Institute for Electromagnetic Detection of The Environment, (ICEMB-CNR-IREA), 80124 Naples, Italy
| |
Collapse
|
6
|
Zheng Z, Huang G, Gao T, Huang T, Zou M, Zou Y, Duan S. Epigenetic Changes Associated With Interleukin-10. Front Immunol 2020; 11:1105. [PMID: 32582189 PMCID: PMC7287023 DOI: 10.3389/fimmu.2020.01105] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 05/06/2020] [Indexed: 12/11/2022] Open
Abstract
IL-10 is a regulator of inflammation and immunosuppression. IL-10 regulates a variety of immune cells to limit and stop the inflammatory response, and thus plays an important role in autoimmune diseases, inflammatory diseases and cancer. IL-10 is closely related to epigenetic modification, in which changes in DNA methylation of IL-10 gene can affect mRNA and protein levels of IL-10. In addition, changes in histone modifications, especially histone acetylation, can also lead to abnormal expression of IL-10 mRNA. At the same time, a handful of IL-10 related microRNAs (miRNAs) are found to be aberrantly expressed in multiple diseases. Besides, long non-coding RNA (lncRNA) growth arrest specific transcript 5 (GAS5) also inhibits IL-10 expression. Here, we reviewed the epigenetic changes related to IL-10 in various diseases, as well as the regulation of IL-10 gene expression in various diseases by epigenetic modifications such as DNA methylation, histone modification, miRNA, and lncRNA.
Collapse
Affiliation(s)
- Zhonghua Zheng
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Gang Huang
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Tong Gao
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Tianyi Huang
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Mengsha Zou
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Yuhao Zou
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| | - Shiwei Duan
- Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, China
| |
Collapse
|